Visulex Product Pipeline: Indications
Wide Range of Product Development Programs
Our lead technology is DSP-Visulex which combines a proprietary high concentration solutions of dexamethasone sodium phosphate and our Visulex-P technology. DSP-Visulex can address a wide range of ocular inflammation related disease. Potential in licensing of bioactive agents can address a full pipeline of partnering and product development opportunities in ophthalmology. Click here to see how Visulex-P works.
Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, called the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, leading to permanent vision loss. There are 3 types of uveitis. They are based on which part of the uvea is affected. Swelling of the uvea near the front of the eye is called anterior uveitis. Swelling of the uvea in the middle of the eye is called intermediate uveitis. Swelling of the uvea toward the back of the eye is called posterior uveitis. Symptoms can develop gradually and last for many years.
Post Operative Ocular Pain and Inflammation and other Related Anterior Eye Disease Indications
Although recent innovations in surgical techniques and intraocular lenses have improved results, inflammation is still a common side effect following cataract surgery. Postoperative inflammation can cause eye pain, photophobia, intraocular pressure increases, as well as increase the likelihood of cystoid macular edema, synechia formation, posterior capsule opacification, and secondary glaucoma. All of these associated conditions can prolong visual recovery time, enlarge the treatment burden through additional office visits and elevate the risk of poor visual outcomes.
Diabetic Macular Edema
Diabetic Macular Edema is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, these blood vessels begin to build up pressure in the eye and leak fluid, causing DME. DME usually takes on two forms: focal DME, which occurs because of abnormalities in the blood vessels in the eye; and diffuse DME, which occurs because of widening/swelling retinal capillaries (very thin blood vessels
Age-related Macular Degeneration
Age-related macular degeneration — also called macular degeneration, AMD or ARMD — is deterioration of the macula, which is the small central area of the retina of the eye that controls visual acuity. The health of the macula determines our ability to read, recognize faces, drive, watch television, use a computer, and perform any other visual task that requires us to see fine detail. Macular degeneration is the leading cause of vision loss among older Americans, and due to the aging of the U.S. population, the number of people affected by AMD is expected to increase significantly in the years ahead. AMD patients typically must receive monthly intravitreal (IVT) injections for the rest of their life. Not only do many AMD patients hate IVT injections but this treatment given its long term frequency presents a significant risk of intraocular infection. Moreover, IVT injections are expensive because they are considered a special procedure that requires a well-trained retinal specialist to perform.